An Act establishing a pilot program for access to regulated psilocybin

HD 4196 establishes a two-year pilot program (starting January 2026) allowing research into psilocybin-assisted therapy for adults aged 21+ with specific conditions like PTSD, end-of-life distress, or depression in designated areas. The program, managed by the Department of Public Health, will partner with universities and community-based providers (such as mental health clinics and hospices) to conduct studies under FDA-approved pathways. Key provisions include developing professional standards, training facilitators, collecting data on efficacy and cost, and reporting annually to legislative committees on statewide impacts and potential MassHealth coverage feasibility. The pilot focuses solely on research in controlled settings, not legalization, with funding covering administration, training, data collection, and community education.